Mobile Device (Android & iOS) Monovaccine (Epstein – Barr virus) Market is the largest segment driving the growth of Monovaccine (Epstein – Barr virus) Market
Epstein-Barr virus causes infectious mononucleosis and is associated with several cancers. A monovaccine against EBV will help prevent infectious mononucleosis and reduce cancer risk.It offers immunization against Epstein-Barr virus to control diseases caused by it.
The global Monovaccine (Epstein – Barr virus) Market is estimated to be valued at US$ 10.42 Bn in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the Monovaccine (Epstein – Barr virus) market is the focus of players on developing an intranasal vaccine, as it provides an easy mode of administration and is a non-invasive alternative to intramuscular injection. Intranasal vaccines induce both systemic and mucosal immunity, eliciting a strong immune response. For instance, in 2022 Baxter International initiated Phase 1 clinical trials of an intranasal EBV vaccine candidate to prevent infectious mononucleosis and reduce cancers associated with EBV.
SWOT Analysis
Strength: The monovaccine market for Epstein – Barr virus sees a global need for effective prevention and treatment against the virus. Researchers have been working to develop a vaccine for decades.
Weakness: Research on this vaccine is still ongoing and a viable product is yet to receive regulatory approvals. Public awareness about the virus and the need for vaccination is relatively low.
Opportunity: With increasing research funding and collaborations, an approved monovaccine can address a major public health concern. It represents a large potential market and long patent life.
Threats: Other competing drug developers may find alternatives or substitutes. Regulations could affect research timelines and profitability. Virus epidemiology may change over time.
Key Takeaways
The global Monovaccine (Epstein – Barr Virus) Market Demand is expected to witness high growth, exhibiting a CAGR of 5.3% over the forecast period, due to increasing research investments from governments and healthcare agencies. This virus is associated with several cancers and diseases, emphasizing the need for a prevention vaccine.
Regional analysis: North America currently dominates the monovaccine market for Epstein – Barr virus due to extensive research activities in the region. However, Asia Pacific is expected to emerge as the fastest growing regional market owing to rising healthcare expenditures, growing medical tourism, and increasing collaborative vaccine development programs between countries.
Key players operating in the monovaccine (Epstein – Barr virus) market are Pfizer Inc., GlaxoSmithKline, Biomed Pvt. Ltd., Serum Institute of India, Baxter International, Sanofi S.A., Neuro Biotech, Merck, JN-International, CNGB. These players are focused on pipeline expansion and targeting high prevalence populations through geography-specific product offering and marketing strategies.
Some of the recent market developments include Pfizer initiating phase 1 clinical trials in 2022, GlaxoSmithKline acquiring vaccine portfolio of Spain-based Birmex, and Serum Institute investing over $50 million in Epstein – Barr virus vaccine research in collaboration with US-based scientists. Such initiatives are expected to boost market prospects.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it